The Race for COVID-19 Vaccines and Therapies: Risks in R&D, Product Safety and Environmental Concerns
JULY 22, 2020
- The pressing demand for therapies and vaccines against SARS-CoV-2 amplifies ESG risks of drug development and production.
- ISS ESG data shows that many companies are ill prepared to meet the new challenges as effective risk mitigation procedures are lacking.
- The need for effective treatments for and prevention of COVID-19 should not come at the expense of the environment. It is crucial that companies include environmental considerations in early R&D and ensure high standards for biosafety when handling biological agents.
- ISS ESG’s Corporate Rating can help investors identify leaders and laggards with regard to the key challenges faced by the industry today.